# US 2021/0275443 A1 · Sustained-release injection preparation containing donepezil derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275443 A1
- Document ID: US20210275443A1
- Status: Published application
- Kind: A1
- Application number: 17/261,379
- Filed: 2019-05-30
- Published: 2021-09-09
- Earliest claimed: 2018-05-30
- Assignees: Nanjing Noratech Pharmaceutical Co., Ltd.
- Applicants: Nanjing Noratech Pharmaceutical Co., Ltd.
- Inventors: Cuixia ZHANG; Fei LIU; Wei LIU; Lulu WANG; Deyan YIN
- Web page: https://patentgrep.com/patent/US20210275443A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are a sustained-release injection preparation containing a donepezil derivative in the form of a suspension, and the use of the preparation in the preparation of a medicament for treating diseases caused by abnormal acetylcholinesterase activity.

## Claims

### Claim 1

A sustained-release injection preparation in the form of a suspension, wherein the injection preparation comprises a compound of formula (I), a wetting agent and a suspending agent,
wherein:
R is a C5-17 alkyl.

### Claim 2 (depends on 1)

The sustained-release injection preparation of claim 1, wherein the wetting agent is one or more selected from the group consisting of polysorbates, polyoxyethylene castor oils, poloxamers, tylosamers, povidone, lecithin, polyoxyethylene hydrogenated castor oil, bile salt and polyoxyethylene polyoxypropylene ether block copolymer; and preferably one or more selected from the group consisting of polysorbate 20, polysorbate 40 and polysorbate 80; and more preferably, polysorbate 80.

### Claim 3 (depends on 1)

The sustained-release injection preparation of claim 1, wherein the suspending agent is selected from natural polymer suspending agents, synthetic or semi-synthetic polymer suspending agents; preferably one or more selected from the group consisting of gums, celluloses, carbopol, povidone, dextran and polyethylene glycol; more preferably one or more selected from the group consisting of sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl cellulose, gum arabic, xanthan gum, povidone and polyethylene glycol; and most preferably, one or more selected from the group consisting of polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 800, polyethylene glycol 1000, polyethylene glycol 1500, polyethylene glycol 4000, polyethylene glycol 6000 and polyethylene glycol 8000.

### Claim 4 (depends on 1)

The sustained-release injection preparation of claim 1, wherein the mixture ratio (weight) of the wetting agent to the suspending agent is 1:0.3 to 1:10, preferably from 1:0.5 to 1:6, and more preferably 1:1, 1:3, 1:3.75, 1:5 or 1:6.

### Claim 5 (depends on 1)

The sustained-release injection preparation of claim 1, wherein the amount of the compound of the formula (I) is 8-22 g/100 ml, the amount of the wetting agent is 0.5-1 g/100 ml, and the amount of the suspending agent is 0.3-5 g/100 ml.

### Claim 6 (depends on 5)

The sustained-release injection preparation of claim 5, wherein the amount of the compound of the formula (I) is 8 g/100 ml, 15 g/100 ml, 17 g/100 ml, 20 g/100 ml or 22 g/100 ml, the amount of the wetting agent is 0.5 g/100 ml, 0.6 g/100 ml, 0.8 g/100 ml or 1 g/100 ml, and the amount of the suspending agent is 0.3 g/100 ml, 0.5 g/100 ml or 3 g/100 ml.

### Claim 7 (depends on 1)

The sustained-release injection preparation of claim 1, wherein the sustained-release injection preparation of the present invention further comprises a buffer agent.

### Claim 8 (depends on 7)

The sustained-release injection preparation of claim 7, wherein the buffer agent is phosphate, preferably disodium hydrogen phosphate, or sodium dihydrogen phosphate.

### Claim 9 (depends on 1)

The sustained-release injection preparation of claim 1, wherein R is selected from n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-tridecyl, n-pentadecyl or N-heptadecyl.

### Claim 10 (depends on 1)

The sustained-release injection preparation of claim 1, wherein R is a C6 alkyl.

### Claim 11 (depends on 10)

The sustained-release injection preparation of claim 10, wherein R is a n-hexyl.

### Claim 12 (depends on 1)

The sustained-release injection preparation of claim 1, wherein the compound of formula (I) is selected from the group consisting of:

### Claim 13 (depends on 1)

The sustained-release injection preparation of claim 1, wherein the period during which the aggregation and sedimentation of particles won't occur after the sustained-release injection suspension of donepezil derivatives is stored at 25° C. or 40° C. is at least 1 month; preferably at least 2-4 months; more preferably at least 5-6 months; and more preferably at least 6 months.

### Claim 14 (depends on 1)

Use of the sustained-release injection preparation of claim 1 in the preparation of a medicament for treating diseases caused by abnormal acetylcholinesterase activity.

### Claim 15 (depends on 14)

The use of claim 14, wherein the diseases is Alzheimer's disease.

### Claim 16 (depends on 14)

The use of claim 14, wherein the medicament is intramuscularly or subcutaneously administered; and preferably, intramuscularly administered.

### Claim 17 (depends on 1)

The sustained-release injection preparation of claim 1, wherein the sustained-release injection preparation is intramuscularly or subcutaneously administered; and preferably, intramuscularly administered.
